ArticleChest2026
Exacerbation Risk by Chronic Proton Pump Inhibitor Use in Obstructive Lung Diseases.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown inconsistent results regarding the use of proton pump inhibitors (PPIs) and the risk on exacerbations in patients with chronic obstructive airway diseases (COADs). RESEARCH QUESTION: Is long-term PPI use associated with exacerbation risk? STUDY DESIGN AND
methodsUsing Belgian nationwide claims-based data of adult patients receiving long-term medication for COADs between 2017 and 2022, we investigated the association between PPI use and exacerbation risk using multivariable Cox models. Based on defined daily doses (DDDs) dispensed during the prior year, dose-dependent associations were assessed by inverse probability of treatment weighted Cox regression models.
resultsAmong 932,135 included patients with COADs, 416,087 patients (44.6%) were PPI users, of whom 57,540 patients (13.8%) received 1-28 DDDs of PPIs, 128,017 patients (30.8%) received 29-180 DDDs, 127,981 patients (30.8%) received 181-365 DDDs, and 102,549 patients (24.6%) received > 365 DDDs in the previous year. Beyond age, sex, smoking, socioeconomic status, exacerbation history, short-acting bronchodilator use, frailty, and comorbidities, PPI use was associated with an increased risk of exacerbations (adjusted hazard ratio [HR], 1.18 [95% CI, 1.17-1.19]). Moreover, compared with patients who did not use PPIs, the risk of exacerbations increased with cumulative DDDs (≤ 28 DDDs: HR, 1.09 [95% CI, 1.07-1.10]; ≤ 180 DDDs: HR, 1.15 [95% CI, 1.14-1.16]; ≤ 365 DDDs: HR, 1.19 [95% CI, 1.18-1.20]; and > 365 DDDs: HR, 1.25 [95% CI, 1.23-1.26]). Sensitivity analyses indicated that the association with exacerbation risk was most pronounced in patients younger than 50 years, who were not frail, and with theoretically increased PPI plasma concentrations, and was not significant when used short-term in patients with gastroesophageal reflux disease.
interpretationCumulative PPI use in patients with obstructive lung diseases was associated with an increase in exacerbation risk. This highlights the need to consider PPI use carefully in clinical respiratory practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.